Product Information

NEVIRAPINE ER 400 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.5213 per EA under NDC 33342023807. Its NADAC has been published 281 times since Aug 8, 2018.

FDA first approved this application on Oct 6, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

NEVIRAPINE ER 400 MG TABLET

NEVIRAPINE
$1.5213per EA

Strength

400 mg/1

NDC

33342023807

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

NEVIRAPINE

Approval Type

Generic (ANDA)

FDA Application

ANDA206879

FDA Approved

10/6/2017

TE Code

AB

On Market Since

10/7/2017

Pharmacological Classes

Cytochrome P450 2B6 Inducers
Cytochrome P450 3A Inducers
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Analog
Non-Nucleoside Reverse Transcriptase Inhibitors

Price Statistics

The NADAC for NEVIRAPINE ER 400 MG TABLET has been published 281 times since Aug 8, 2018, and over the history we have for it it has declined 81.7%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5213 per EA
All-time high$8.3108 (Aug 15, 2018)
All-time low$1.2487 (Jan 21, 2026)
52-week high$1.9836
52-week low$1.2487
Median price$3.2679
Average price$3.2933
Largest weekly change-59.4% (Apr 17, 2024)
Weeks tracked281
Tracking sinceAug 8, 2018

Price History

1W

+0.8%

1M

+0.8%

3M

-3.9%

6M

+17.3%

1Y

-23.3%

3Y

-64.6%

5Y

-64.6%

All

-81.7%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the NEVIRAPINE market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of NEVIRAPINE ER 400 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for NEVIRAPINE ER 400 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $1.5213 per EA (NDC 33342023807), effective Aug 19, 2026.

How has the price of NEVIRAPINE ER 400 MG TABLET changed over time?

Over the history we have for it, the NADAC for NEVIRAPINE ER 400 MG TABLET has declined 81.7%. It has been tracked across 281 weekly CMS publications since Aug 8, 2018.

What are the highest and lowest recorded NADAC prices for NEVIRAPINE ER 400 MG TABLET?

Since Aug 8, 2018, the NADAC for NEVIRAPINE ER 400 MG TABLET has ranged from a low of $1.2487 (Jan 21, 2026) to a high of $8.3108 (Aug 15, 2018), with a median of $3.2679 per EA.

Are there cheaper alternatives to NEVIRAPINE ER 400 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of NEVIRAPINE ER 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures NEVIRAPINE ER 400 MG TABLET?

NEVIRAPINE ER 400 MG TABLET (NDC 33342023807) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.